Dyno Therapeutics — named after the high-risk, high reward mountaineering maneuver where an intrepid climber jumps or swings to the next hold, letting go of all contact points — is pioneering an artificial intelligence (AI)-powered approach to gene therapy. Using machine learning and quantitative high-throughput in vivo experimentation, Dyno Therapeutics is inventing new ways to design viral vectors by focusing on cell-targeting capsid proteins from AAVs . . .
Home Viral Vectors AAV (Adeno-associated virus) Going Viral: Dyno Therapeutics Is Broadening the Reach of In Vivo Gene...

- Viral Vectors
- AAV (Adeno-associated virus)
- Artificial Intelligence
- Drug Discovery
- GEN Edge
- Genome Editing
- Gene Therapy
Going Viral: Dyno Therapeutics Is Broadening the Reach of In Vivo Gene Therapies
With its AI platform, Dyno generates an unprecedented diversity of viral vectors to amplify the range of diseases treatable with genetic medicines.
A model of Dyno Therapeutics’ adeno-associated virus (AAV) capsid with all monomers assembled. The company’s CapsidMap™ platform rapidly discovers and systematically optimizes AAV capsids that significantly outperform current in vivo gene delivery approaches, thereby increasing the scope of diseases treatable with gene therapies. [Dyno Therapeutics]